Methods for reducing cd36 expression

Abstract

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.

1 .- 10 . (canceled) 
     
     
         11 . A method for reducing CD36 expression in a removed organ or a removed tissue, the method comprising contacting the organ or tissue with an effective amount an aromatic-cationic peptide selected from the group consisting of Phe-D-Arg-Phe-Lys-NH 2  and D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 . 
     
     
         12 . The method of  claim 11 , wherein the peptide is D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 . 
     
     
         13 . The method of  claim 11 , wherein the peptide is Phe-D-Arg-Phe-Lys-NH 2 . 
     
     
         14 . The method of  claim 11 , wherein the mammal is a human. 
     
     
         15 . The method of  claim 11 , wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intramuscularly, intracerebroventricularly, or intrathecally.